Proton pump inhibitors in pediatrics: Evaluation of efficacy in GERD therapy

Current Clinical Pharmacology

Volumn 6, Issue 1, 2011, Pages 41-47

  Romano, Claudio ^a   Chiaro, Andrea ^a   Comito, Donatella ^a   Loddo, Italia ^a   Ferraú, Valeria ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Children; GERD; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACHLORHYDRIA; ARTICLE; CANDIDEMIA; CELL HYPERPLASIA; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HIP FRACTURE; HUMAN; HYPERGASTRINEMIA; INTERSTITIAL NEPHRITIS; LONG TERM CARE; NAUSEA; NECROTIZING ENTEROCOLITIS; PATHOPHYSIOLOGY; PEDIATRICS; POLYP; PRIORITY JOURNAL; TREATMENT DURATION;

AGE FACTORS; ANIMALS; CHILD; CHILD, PRESCHOOL; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; INFANT; PROTON PUMP INHIBITORS;

EID: 79953066390     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488411794941296     Document Type: Article

References (98)

1. Orenstein S, Mc Gowan J. Efficacy of conservative therapy as taught in the primary care setting for symptoms suggesting gastroesphageal reflux. J Pediatr 2008; 152: 310-14.
2. Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs 2003; 5(1): 25-40.
3. Repchinsky C. Ed. Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association; 2006.
4. Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted Country, Minnesota. Gastroenterology 2007; 112: 148-56.
5. Chitkara DK, Talley NJ, Weaver AL, et al. Incidence of presentation of common functional gastrointestinal disorders in children from birth to 5 years: a cohort study. Clin Gastroenterol Hepatol 2007; 5: 186-91.
6. Hassal E. Talk is cheap, often effective: symptoms in infants often respond to-non pharmacologic measures. J Pediatr 2008; 152: 301-3.
7. Orenstein SR, Hassal E. Infants and proton pump inhibitors: tribulations, no trials. J Pediatr Gastroentrol Nutr 2007; 45: 395-8.
8. Gupta SK, Hassal E, Chiu Y-L, et al. Presenting symptoms of nonerosive and erosive esophagitis in pediatric patient. Dig Dis Sci 2006; 51: 858-63.
9. Sherman PM, Hassall E, Fagundes-Neto U, et al. A Global, Evidence-Based Consensus on the definition of Gastroesophageal Reflux Disease in the Pediatric Population. Am J Gastroenterol 2009; 104: 1278-95.
10. Bohemer CJ, Clinkenberg-Knol EC, Niezen-de Boer MC, et al. Gastroesophageal reflux disease in intellectually disabled individuals: how often, how serious, how manageable? Am J Gastroenterol 2000; 95: 1868-72.
11. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150: 262-7.
12. El-Serag H. Role of obesity in GORD-related disorders. Gut 2008; 57: 281-4.
13. Button BM, Roberts S, Kotsimbos TC, et al. Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patient with cystic fibrosis before and after lung transplantation. J Heart Lung Transplant 2005; 24: 1522-9.
14. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49: 498-547.
15. Ersin NK, Oncag O, Tumgor G, et al. Oral and dental manifestations of gastroesophageal reflux disease in children: a preliminary study. Pediatr Dent 2006; 28: 279-84.
16. Cerimagic D, Ivkic G, Bilic E. Neuroanatomical basis of Sandyfer's sindrome: a new vagal reflex? Med Hypotheses 2008; 70: 957-61.
17. Kelly EJ, Newell SJ, Brownlee KG, et al. Gastric acid secretion in preterm infants. Early Hum Dev 1993; 35: 215-20.
18. Grand RJ, Watkins JB, Torti FM. Development of the human gastrointestinal tract: a review. Gastroenterology 1976; 70: 790-810.
19. Boyle JT. Acid secretion from birth to adulthood. J Pediatr Gastroenterol Nutr 2003; 37: S12-6.
20. Kelly EJ, Brownlee KG, Newell SJ. Gastric secretory function in the developing human stomach. Early Hum Dev 1992; 31: 163-6.
21. Aihara T, Nakamura E, Amagase K, et al. Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future. Pharmacol Ther 2003; 98: 109-27.
22. Kearns GL, Blumer J, Schexnayder S, et al. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J Clin Pharmacol 2008; 48: 1356-65.
23. Kearns GL, Winter HS. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr 2003; 37 (Suppl 1): S52-9.
24. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006; 44(7): 297-302.
25. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl 3): 27-36.
26. Andersson T, Hassall E, Lundborg P, et al. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 2000; 95: 3101-6.
27. De Wildt SN, Kearns GL, Leeder JS, et al. Cytocrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485-505.
28. Treluyer JM, Gueret G, Cheron G, et al. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/ in-vitro correlation and inducibility. Pharmacogenetics 1997; 7: 441-52.
29. Omari TI, Haslam RR, Lundborg P, et al. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr 2007; 44: 41-4.
30. Omari T, Lundborg P, Sandstrom M, et al. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. J Pediatr 2009; 155: 222-8.
31. Zhang W, Kukulka M, Witt G, et al. Age-dependent Pharmacokinetics of Lansoprazole in Neonates and Infants. Pediatr Drug 2008; 10: 265-274.
32. Litalien C, Théorêt Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44: 441-66.
33. Zhao J, Li J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006; 28: 1868-76.
34. Li J, Zhao J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, openlabel study. Clin Ther 2006; 28: 419-27.
35. Heyman MB, Zhang W, Huang B, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 44: 35-40.
36. James L, Walson P, Lomax K, et al. Study 119 Pediatric Trial Investigators. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single and multiple-dose study. Clin Ther 2007; 29: 2082-92.
37. Barron JJ, Tan H, Spalding J, et al. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr 2007; 45: 421-7.
38. Khoshoo V, Edell D, Thompson A, et al. Are we overprescribing antireflux medications for infants with regurgitation? Pediatrics 2007; 120: 946-9.
39. Omari T, Davidson G, Bondarov P, et al. Pharmacokinetics and acid-suppressive Effects of Esomeprazole in Infants 1-24 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastenterol Nutr 2007; 45: 530-7.
40. Springer M, Atkinson S, North J, Raanan M. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year. Pediatr Drugs 2008; 10: 255-63.
41. Winter H, Kum-Nji P, Mahomedy S, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1 through 11 months with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2010; 50(6): 609-18.
42. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebocontrolled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154: 514-520.
43. Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003; 143: 219-23.
44. Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker P, Illueca M. Esomeprazole for the treatment of gastroesophageal reflux disease (GERD) in infants. Gastroenterology 2009; 136(5 Suppl 1): A-504 Abstract T1123.
45. G, Baker R, Tsou V, et al. Randomized, double-blind clinical outcomes, safety, and tolerability study of pantoprazole delayed- release granules in children aged 1 to 5 years with endoscopically proven symptomatic gastroesophageal reflux disease (GERD). Gastroenterology 2009; 136(5 Suppl 1): A-444 Abstract M1909.
46. Tolia V, Wuerth A, Thomas R. Diagnostic interpretation of extended pH monitoring: is there a single best method? Dig Dis Sci 2005; 50: 94-9.
47. Fiore JM, Arko M, Churbock K, Hibbs AM, Martin RJ. Technical limitations in detection of gastroesophageal reflux in neonates. J Pediatr Gastroenterol Nutr 2009; 49: 177-82.
48. Orenstein SR, Shalaby TM, Cohn JF: Reflux symptoms in 100 normal infants: diagnostic validity of the infant gastroesophageal reflux questionnaire. Clin Pediatr (Phila) 1996; 35: 607-14.
49. Kleinman L, Rothman M, Strauss R, et al. The infant gastroesophageal reflux questionnaire revised: development and validation as an evaluative instrument. Clin Gastroenterol Hepatol 2006; 4: 588-96.
50. Gerson LB. A Little weight gain, how much gastroesophageal disease? Gastroenterology 2006; 131: 1644-6.
51. Rudolph CD, Mazur Lj, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendation of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32 (Suppl 2): S1-S3.
52. Oreinstein SR, Blummer JL, Faessel HM, et al. Ranitidine 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2002; 16: 899-907.
53. Nwokolo CU, Smith JT, Gavey C, et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990; 4(Suppl 1): 29-45.
54. Richardson P, Hawkey CJ, Stack WA. Proton Pump Inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56(3): 307-335.
55. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91. 1391 e1-5.
56. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000; 137: 800-7.
57. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965-73.
58. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 1434-42.
59. Fossmark R, Johnsen G, Johanessen E, et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005; 21: 149-54.
60. Bjornsson E, Abrahamsson H, Simren M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a doubleblind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24: 945-54.
61. Hassall E. for the International Pediatric Omeprazole Study Group. Omeprazole for maintenance therapy of erosive esophagitis in children. Gastroenterology 2000; 118: A658.
62. Boccia G, Manguso F, Miele E, et al. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am J Gastroenterol 2007; 192: 1291-7.
63. Stordal K, Johannesdottir GB, Bentsen BS, et al. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. Arch Dis Child 2005; 90: 956-60.
64. Neubert A, Dormann H, Weiss J, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 2004; 27: 1059-67.
65. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88: 965-68.
66. Buecheler R, Schwab M, Moerike K, et al. Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ 2002; 324: 1311-2.
67. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal 1999; Ed 80: F142-5.
68. McIntyre J, Conroy S, Avery A, et al. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000; 83: 498-501.
69. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off-label drug use in pediatric wards in European countries. European network for drug investigation in children. BMJ 2000; 320(7227): 79-82.
70. Guillet R, Stoll Bj, Cotton CM, et al. For members of the national institute of child health and human development neonatal research network. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006; 117: e137-42.
71. Tafuri G, Trotta F, Leufkens HGM, et al. Off-label use of medicines in children: can available evidence avoid useless pediatric trials? Eur J Clin Pharmacol 2009; 65: 209-16.
72. Forgacs I. Overprescribing proton pump inhibitors: Is expensive and not evidence based. BMJ 2008; 336: 2-3.
73. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25: 333-40.
74. Mat Saad AZ, Collins N, Lobo MM, O'Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 2005; 59: 31-4.
75. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001; 23: 116-7.
76. Pham CQD, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006; 40: 1261-6.
77. Batuwitage B, Kingham JCG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83: 66-8.
78. Esplugues JV, Martí-Cabrera M, Ponce J. Safety of proton pump inhibitors. Med Clin (Barc) 2006; 127:790-5.
79. Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 2008; 53: 385-93.
80. Gilger MA, Tolia V, Vandenplas Y, et al. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2008; 46: 524-33.
81. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150: 262-7.
82. Drut R, Altamirano E, Cueto Rua E. Omeprazole-associated changes in the gastric mucosa of children. J Clin Pathol 2008; 61: 754-6.
83. Hassall E, Dimmick JE, Israel DM. Parietal cell hyperplasia in children receiving omeprazole. Gastroenterology 1995; 108: A110.
84. Pashankar DS, Israel DM. Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr 2002; 35: 658-62.
85. Hassall E, Owen D, Kerr W, et al. Gastric histology in children treated with proton pump inhibitors (PPIs) long-term. Gastroenterology 2008; 134: A174.
86. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and communityacquired pneumonia in children. Pediatrics 2006; 117: e817-20.
87. Canani RB, Terrin G. Gastric acidity inhibitors and the risk of intestinal infections. Curr Opin Gastroenterol 2010; 26: 31-5.
88. Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006; 117: e137-42.
89. Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20: 1119-24.
90. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acidsuppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5: 1418-23.
91. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006; 23: 3-10.
92. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57: 422-8.
93. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53.
94. den Elzen WP, Groeneveld Y, de Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008; 27: 491-7.
95. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28: 951-9.
96. Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol 2007; 68: 65-72.
97. E, Jensen-Jarolim E. The role of protein digestibility and antacids on food allergy outcomes. J Allergy Clin Immunol 2008; 121: 1301-8. quiz 1309-10.
98. Hassall E. Step-up and step-down approaches to treatment of gastroesophageal reflux disease in children. Curr Gastroenterol Rep 2008; 10: 324-31.